Delivery Order SPE2DB22D2211-SPE2DB25FSDZN
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,480.40 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/mL SureClick auto-injectors. The contract was competitively awarded without set-aside designation and carries an ultimate completion date of July 29, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, valued at $1,214.32 with a firm fixed price. The contract, which was competitively awarded without a set-aside designation, has an ultimate completion date of August 14, 2025, and represents a child order under AmerisourceBergen's broader pharmaceutical supply relationship with DLA. The place of performance is listed as the vendor's location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $1,962.21 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of July 22, 2025. This competitively awarded, firm fixed-price delivery order was issued under a non-set-aside procurement and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Repatha is a prescription medication used to lower cholesterol levels, and this delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors valued at $2,902.67, with an ultimate completion date of September 12, 2025. This competitively awarded, firm fixed-price delivery order was issued without a set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's existing contract vehicle...
- The Defense Logistics Agency has awarded a delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, valued at $10,380.32 under a firm fixed price contract. The award was issued on August 6, 2025, with an ultimate completion date of August 7, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order carries no set-aside designation and was competitively awarded through the federal...
- The Defense Logistics Agency awarded a $6,884.63 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of July 25, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply relationship with the...
- The Defense Logistics Agency awarded a $34,401.14 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector medication, with an ultimate completion date of September 9, 2025. This is a competitively awarded, firm fixed-price delivery order with no set-aside designation. The award was issued on September 8, 2025, with performance to be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Repatha is a prescription medication...
- The Defense Logistics Agency awarded a delivery order valued at $1,041.42 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with a completion date of July 23, 2025. This non-competitive, firm fixed-price delivery order was issued on July 22, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Repatha is a prescription medication used to treat high cholesterol and reduce the risk of cardiovascular disease. This...
- The Defense Logistics Agency awarded a delivery order valued at $5,707.30 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with performance at the contractor's Conshohocken, Pennsylvania facility. This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 28, 2025, and represents a non-set-aside procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical supply vendor, fulfills this...
- The Defense Logistics Agency awarded a delivery order valued at $7,668.64 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of August 29, 2025. This non-set-aside, competitively awarded contract employs firm fixed pricing and represents a continuation order under AmerisourceBergen's existing pharmaceutical supply relationship with DLA. The place of performance is the vendor's corporate office in Conshohocken, Pennsylvania. This...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSDZNDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $34,507.05 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of September 3, 2025. This competitively awarded, firm fixed-price delivery order was issued under a non-set-aside procurement and represents a single transaction for pharmaceutical supply to support federal medical needs. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a total value of $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Repatha (evolocumab) is a PCSK9 inhibitor used for cholesterol management, reflecting the company's role in delivering specialty medications across multiple therapeutic domains to the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $34.5k | 9/2/25 |